Delta-Fly Pharma (TSE:4598) Debt-to-Equity: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4598 Delta-Fly Pharma Inc TSE:4598
26 GF Score
Price 円121.00
! 2 Warning Signs
View Full Analysis

What is Delta-Fly Pharma Debt-to-Equity?

Delta-Fly Pharma TSE:4598 +9.01% 26 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates TSE:4598 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 963 Biotechnology companies, Delta-Fly Pharma ranks worse than 103842.06% on this metric.

Delta-Fly Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was 円0.00 Mil. Delta-Fly Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was 円0.00 Mil. Delta-Fly Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was 円33.98 Mil. Delta-Fly Pharma's debt to equity for the quarter that ended in Mar. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Delta-Fly Pharma's Debt-to-Equity or its related term are showing as below:

During the past 10 years, the highest Debt-to-Equity Ratio of Delta-Fly Pharma was 0.03. The lowest was 0.00. And the median was 0.01.

TSE:4598's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Delta-Fly Pharma  (TSE:4598) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Delta-Fly Pharma Debt-to-Equity Related Terms

Delta-Fly Pharma Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Delta-Fly Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delta-Fly Pharma Debt-to-Equity Chart

Delta-Fly Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Delta-Fly Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4598 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison

For the Biotechnology subindustry, Delta-Fly Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Delta-Fly Pharma Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Delta-Fly Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Delta-Fly Pharma's Debt-to-Equity falls into.


TSE:4598
26GF Score
Delta-Fly Pharma Inc TSE:4598
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delta-Fly Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Delta-Fly Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 33.981
=0.00

Delta-Fly Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 33.981
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Delta-Fly Pharma (TSE:4598) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Delta-Fly Pharma and its competitors. According to the industry distribution chart, Delta-Fly Pharma ranks #999999 out of 963 companies in the Biotechnology industry.
Is Delta-Fly Pharma's Debt-to-Equity too high?
Delta-Fly Pharma's current Debt-to-Equity is 0.00. Based on the distribution chart, Delta-Fly Pharma ranks #999999 out of 963 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Delta-Fly Pharma has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Delta-Fly Pharma's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Delta-Fly Pharma ranks #999999 out of 963 companies for Debt-to-Equity. This places Delta-Fly Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Delta-Fly Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delta-Fly Pharma's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delta-Fly Pharma stock overvalued right now?
Delta-Fly Pharma (TSE:4598) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Delta-Fly Pharma's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Delta-Fly Pharma (TSE:4598), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Delta-Fly Pharma Business Description

Address 37-5, Miyajima Nishikino, Kawauchi-cho, Tokushima, JPN, 771-0116
Delta-Fly Pharma Inc is a Japan-based company mainly engaged in the discovery and development of gentle anti-cancer agents with module technology.
26GF Score

Get the complete analysis for TSE:4598

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円121.00
Price